Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Enzyme Engineering . These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel aminotransferase mutants enable high-yield sitagliptin synthesis. Cost-effective, scalable pharma intermediate solution with >99% ee.
Novel transaminase mutant enables high-yield sitagliptin intermediate synthesis with superior stereoselectivity and scalable biocatalytic process efficiency for global supply.
Patent CN121406594A reveals XR21 mutant for xylitol. Enhances purity and reduces downstream costs for food additive manufacturing supply chains.
Patent CN107889505B reveals a novel enzymatic route for NMN production, eliminating expensive PRPP substrates to ensure cost-effective and scalable supply chain solutions.
Patent CN108866021B details a novel transaminase mutant for synthesizing sitagliptin intermediates with >99% ee. Discover cost-effective biocatalytic solutions for API manufacturing.
Novel omega-aminotransferase mutant enables high-yield sitagliptin intermediate production with 99% ee value and reduced solvent constraints for global supply chains.
Patent CN116396950A reveals a novel carboxylesterase mutant for efficient (R)-3-cyclohexene-1-carboxylic acid production, offering superior stereoselectivity and scalable biocatalysis for API intermediates.
Patent CN114317472B details a novel biocatalytic route for (S)-nornicotine using immobilized imine reductase, offering superior purity and scalable manufacturing for pharmaceutical intermediates.
Patent CN115896060A reveals a novel ω-transaminase mutant for silodosin synthesis, offering >99% ee and scalable biocatalysis for reliable supply chains.
Patent CN115725484B reveals dual-enzyme system for D-psicose. Reduces costs via glucose substrate. Reliable supplier for high-purity food additives.
Patent CN119709677B reveals high-yield enzymatic synthesis technology. Offers significant cost reduction in pharmaceutical intermediates manufacturing and enhanced supply chain reliability for buyers.
Novel S173Q/Q360Y mutant enzyme boosts D-alanine yield by 20% and stability 3-fold, offering cost-effective pharma intermediate solutions.
Patent CN118147114A reveals beta-glucosidase mutant for phloretin. Enables cost reduction in flavonoid manufacturing and reliable supply chain scalability.
Patent CN106995807A enables high-purity Sitagliptin intermediate synthesis via recombinant transaminase, offering supply chain stability and cost efficiency.
Patent CN116949024B reveals mutant enzyme boosting conversion. Offers cost reduction and supply reliability for pharmaceutical intermediate manufacturing.
Patent CN119082064B reveals mutant carbonyl reductase for Pro-Xylane. High yield, low cost, scalable biocatalysis for cosmetic manufacturers.
Patent CN110283800A details a novel enzymatic route for α-ketoglutarate. Discover cost reduction in nutritional ingredients manufacturing and high-purity supply chain advantages.
Patent CN113528472B details a novel P450 BM3 mutant route for Trenbolone Acetate. Discover cost reduction in steroid manufacturing and high-purity intermediate supply strategies.
Patent CN111662889B discloses a novel ketoreductase mutant enabling efficient synthesis of Darunavir intermediates with high substrate loading and reduced costs.
Patent CN108690836B details a mutated cyclohexanone monooxygenase for high-conversion esomeprazole synthesis, offering superior purity and scalability for API manufacturers.